Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo

Carcinogenesis

Volumn 29, Issue 10, 2008, Pages 2001-2010

  Wang, Thomas T Y ^a   Hudson, Tamaro S ^b   Wang, Tien Chung ^c   Remsberg, Connie M ^d   Davies, Neal M ^d   Takahashi, Yoko ^e   Kim, Young S ^b   Seifried, Harold ^b   Vinyard, Bryan T ^f   Perkins, Susan N ^g   Hursting, Stephen D ^g,h  

^a BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

^e NATIONAL FOOD RESEARCH INSTITUTE   (Japan)

^f AGRICULTURAL RESEARCH SERVICE   (United States)

^g UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^h UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; ESTRADIOL; KALLIKREIN; KALLIKREIN 3; RESVERATROL; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION REGULATION; HORMONE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL PROLIFERATION; ESTRADIOL; GENE EXPRESSION PROFILING; HUMANS; MALE; METRIBOLONE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STILBENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 53349152994     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn131     Document Type: Article

References (48)

1. Jemal,A. et al. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66.
2. Taplin,M.E. et al. (2004) Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. J. Cell. Biochem., 91, 483-490.
3. Ho,S.M. (2004) Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem., 91, 491-503.
4. Renehan,A.G. et al. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet, 363, 1346-1353.
5. Lieberman,R. (2002) Chemoprevention of prostate cancer: Current status and future directions. Cancer Metastasis Rev., 21, 297-309.
6. Moschos,S.I. et al. (2002) The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63, 317-332.
7. So,A.I. et al. (2003) Androgens and prostate cancer. World J. Urol., 21, 325-337.
8. Kris-Etherton,P.M. et al. (2002) Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med., 113, 71S-88S.
9. Stewart,J.R. et al. (2003) Resveratrol: A candidate nutritional substance for prostate cancer prevention. J. Nutr., 133, 2440S-2443S.
10. Hain,R. et al. (1990) Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant Mol. Biol., 15, 325-335.
11. Bhat,K.P.L. et al. (2001) Biological effects of resveratrol. Antioxid. Redox. Signal., 3, 1041-1064.
12. Goldberg,D.M. et al. (1996) Method to assay the concentrations of phenolic constituents of biological interest in wines. Anal. Chem. 68, 1688-1694.
13. Baur,J.A. et al. (2006) Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov., 5, 493-506.
14. Jang,M. et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-220.
15. Whitehead,T.P. et al. (1995) Effect of red wine ingestion on the antioxidant capacity of serum. Clin. Chem., 41, 32-35.
16. Gehm,B.D. et al. (2004) Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J. Steroid Biochem Mol. Biol., 88, 223-234.
17. Hsieh,T.C. et al. (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res., 249, 109-115.
18. Kim,Y.A. et al. (2003) Antiproliferative effect of resveratrol in human prostate carcinoma cells. J. Med. Food, 6, 273-280.
19. Kuwajerwala,N. et al. (2002) Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res., 62, 2488-2492.
20. Lin,H.Y. et al. (2002) Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J. Urol., 168, 748-755.
21. Narayanan,B.A. et al. (2003) Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int. J. Cancer, 104, 204-212.
22. Jones,S.B. et al. (2005) Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol. Biomarkers Prev., 14, 596-604.
23. Nelson,P.S. et al. (2002) The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl Acad. Sci. USA, 99, 11890-11895.
24. Huang,H. et al. (2002) The role of the androgen receptor in prostate cancer. Crit. Rev. Eukaryot. Gene Expr., 12, 193-207.
25. Takahashi,Y. et al. (2007) 17Beta-Estradiol differentially regulates androgen-responsive genes through estrogen receptor-beta- and extracellular-signal regulated kinase-dependent pathways in LNCaP human prostate cancer cells. Mol. Carcinog., 46, 117-129.
26. Takahashi,Y. et al. (2006) Molecular signatures of soy-derived phytochemicals in androgen-responsive prostate cancer cells: A comparison study using DNA microarray. Mol. Carcinog., 45, 943-956.
27. Takahashi,Y. et al. (2006) Genistein affects androgen-responsive genes through both androgen- and estrogen-induced signaling pathways. Mol. Carcinog., 45, 18-25.
28. Kelland,L.R. (2004) Of mice and men: Values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer, 40, 827-836.
29. Marier,J.F. et al. (2002) Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther., 302, 369-373.
30. Zhou,J.R. et al. (1999) Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr., 129, 1628-1635.
31. Cher,M.L. et al. (1995) Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate, 26, 87-93.
32. Hunter,A.L. et al. (2005) Detection of apoptosis in cardiovascular diseases. Methods Mol. Med., 112, 277-289.
33. Cao,G. et al. (2002) Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am. J. Physiol. Cell Physiol., 282, C1181-C1190.
34. Littell,R.C. et al. (2006) SAS® for Mixed Models. 2nd edn. 814p. Cary, NC.
35. SAS Institute Inc. (2002-2007) SAS® v9.1. SAS Institute, Inc., Cary, NC.
36. Majumder,P.K. et al. (2005) Akt-regulated pathways in prostate cancer. Oncogene, 24, 7465-7474.
37. Shaw,R.J. et al. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 424-430.
38. Xu,Y. et al. (2006) Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res., 66, 7783-7792.
39. El-Deiry,W.S. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
40. Hsieh,T.C. et al. (2000) Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res., 20, 225-228.
41. Benitez,D.A. et al. (2007) Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: Modulation of the phosphoinositide 3-kinase pathway. Br. J. Cancer, 96, 1595-1604.
42. Pozo-Guisado,E. et al. (2004) Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: Relevance in cell proliferation. Int. J. Cancer, 109, 167-173.
43. Aziz,M.H. et al. (2006) Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins. Mol. Cancer Ther., 5, 1335-1341.
44. Karan,D. et al. (2001) Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. Clin. Cancer Res., 7, 3472-3480.
45. Aggarwal,B.B. et al. (2004) Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 24, 2783-2840.
46. Reagan-Shaw,S. et al. (2007) Dose translation from animal to human studies revisited. FASEB J. 22, 659-661.
47. Boocock,D.J. et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev., 16 1246-1252.
48. Harper,C.E. et al. (2007) Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis, 28, 1946-1953.